Tag: Glatiramer

Cardiology

Glatiramer acetate protects against oxygen-glucose deprivation/reperfusion-induced injury by inhibiting Egr-1 in H9c2 cells.

Newsemia
Related Articles Glatiramer acetate protects against oxygen-glucose deprivation/reperfusion-induced injury by inhibiting Egr-1 in H9c2 cells. Mol Immunol. 2020 Feb 17;120:61-66 Authors: Du J, Lv W,...
Neurology

Response to the Letter-to-the Editor ENSCI-D-18-00074 concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19–30.https://doi.org/10.1016/j.ensci.2018.05.006

Newsemia
We appreciate the readers’ interest in our paper [1] and we encourage the open scientific debate on the complexity of glatiramer acetate and the comparability...
Latest News

Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis

Newsemia
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced safety and tolerability results representing 25 years of data from the open-label extension study...
Neurology

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone

Newsemia
For more than 20 years, Copaxone (glatiramer acetate, Teva), a non-biological complex drug, has been a safe and effective treatment option for multiple sclerosis. In...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World